Article
Oncology
Melanie Royce, Christy L. Osgood, Anup K. Amatya, Mallorie H. Fiero, C. J. George Chang, Tiffany K. Ricks, Krithika A. Shetty, Jeffrey Kraft, Junshan Qiu, Pengfei Song, Rosane Charlab, Jingyu Yu, Kathryn E. King, Anshu Rastogi, Brian Janelsins, Wendy C. Weinberg, Kathleen Clouse, Vicky Borders-Hemphill, Lindsey Brown, Candace Gomez-Broughton, Zhong Li, Thuy Thanh Nguyen, Zhihao Qiu, Anh-Thy Ly, Suyoung Chang, Tingting Gao, Chi-Ming Tu, Bellinda King-Kallimanis, William F. Pierce, Kelly Chiang, Clara Lee, Kirsten B. Goldberg, John K. Leighton, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Laleh Amiri-Kordestani
Summary: Margetuximab-cmkb in combination with chemotherapy was granted regular FDA approval for the treatment of HER2-positive metastatic breast cancer patients who have received two or more prior anti-HER2 regimens. The SOPHIA study demonstrated that margetuximab had a longer median progression-free survival compared to trastuzumab when both were combined with chemotherapy. Infusion-related reactions were reported as important safety signals associated with margetuximab plus chemotherapy.
CLINICAL CANCER RESEARCH
(2022)
Article
Immunology
Sofia Batalha, Catarina Monteiro Gomes, Catarina Brito
Summary: This study presents a unique human 3D model for studying the immune effects of anti-HER2 biologicals, which can be used to test novel therapy regimens and improve anti-tumor immune function.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Pharmacology & Pharmacy
Marta Sevieri, Serena Mazzucchelli, Linda Barbieri, Stefania Garbujo, Stephana Carelli, Arianna Bonizzi, Federica Rey, Camilla Recordati, Matteo Recchia, Raffaele Allevi, Leopoldo Sitia, Carlo Morasso, Pietro Zerbi, Davide Prosperi, Fabio Corsi, Marta Truffi
Summary: The study demonstrates the potential of a nanoconjugate called H-TZ, consisting of TZ and HFn, in delivering TZ to the brain and combating HER2+ breast cancer brain metastasis. H-TZ efficiently reduces tumor growth, avoids cardiotoxicity, and shows promise for managing BC metastatic to the brain.
PHARMACOLOGICAL RESEARCH
(2023)
Review
Oncology
Alejandro Garcia-Alvarez, Andri Papakonstantinou, Mafalda Oliveira
Summary: Development of brain metastases is a significant event for patients with breast cancer, particularly those with HER2-positive tumors. Advances in targeted therapy against the HER2 receptor have improved management of HER2-positive breast cancer. Despite these improvements, brain metastases continue to be a challenge, highlighting the need for further research and innovative treatment strategies.
Article
Multidisciplinary Sciences
Edward Seung, Zhen Xing, Lan Wu, Ercole Rao, Virna Cortez-Retamozo, Beatriz Ospina, Liqing Chen, Christian Beil, Zhili Song, Bailin Zhang, Mikhail Levit, Gejing Deng, Andrew Hebert, Patrick Kirby, Aiqun Li, Emma-Jane Poulton, Rita Vicente, Audrey Garrigou, Peter Piepenhagen, Greg Ulinski, Michele Sanicola-Nadel, Dinesh S. Bangari, Huawei Qiu, Lily Pao, Dmitri Wiederschain, Ronnie Wei, Zhi-yong Yang, Gary J. Nabel
Summary: A trispecific antibody targeting HER2 and T cells can inhibit breast cancer cell proliferation by stimulating CD4 T cells, and induce tumor regression in a humanized mouse model.
Review
Biochemistry & Molecular Biology
Eleni Triantafyllidi, John K. Triantafillidis
Summary: Trastuzumab biosimilars have shown significant advantages in the treatment of HER-positive breast cancer, particularly in cases of metastatic breast cancer. This systematic review provides valuable insights into the efficacy, safety, and cost-benefit ratio of available trastuzumab biosimilars, but further research is needed to assess cost-effectiveness and the success rate of combination therapies with other anticancer drugs.
Review
Oncology
Tresa M. McGranahan, Alipi Bonm, Jennifer M. Specht, Vyshak Venur, Simon S. Lo
Summary: This paper reviews the treatment options for patients with HER2+ breast cancer brain metastasis and provides a simplified algorithm for when to consider delaying local treatments.
Article
Oncology
Ana Carla Castro-Guijarro, Angel Matias Sanchez, Marina Ines Flamini, Christoph F. A. Vogel
Summary: This study aims to identify biomarkers for predicting disease progression and therapy efficacy in HER2-positive breast cancer, as well as to overcome resistance. Combining anti-HER2 therapies shows potential in inhibiting cell adhesion and migration critical for cancer metastasis. Deregulated proteins in resistant cells may serve as potential biomarkers of therapy response and resistance. These findings are promising for personalized breast cancer management to maximize the safety and efficacy of anti-HER2 therapies.
Article
Chemistry, Multidisciplinary
Bolong Tao, Ruoxin Du, Xiangmei Zhang, Bo Jia, Yuan Gao, Yipu Zhao, Yunjiang Liu
Summary: A novel biomimetic nanoplatform was developed to target HER2-positive breast cancer brain metastasis. This nanoplatform, consisting of chimeric antigen receptor-natural killer (CAR-NK) cell-derived exosomes and a nanobomb, successfully crossed the blood-brain barrier and selectively targeted HER2+ breast cancer cells. By disrupting ferroptosis defense mechanisms, it enhanced the effectiveness of antitumor treatment.
JOURNAL OF CONTROLLED RELEASE
(2023)
Article
Oncology
Wendong Bai, Hongyan Peng, Jiarui Zhang, Yongmei Zhao, Zhijun Li, Xuelian Feng, Jiang Zhang, Fei Liang, Li Wang, Nan Zhang, Yize Li, Huayu Zhu, Qiuhe Ji
Summary: This study identifies the long noncoding RNA LINC00589 as a key regulator in breast cancer, affecting resistance to HER2-targeted therapy, cancer stem cell properties, and chemoresistance. The study reveals the molecular mechanisms underlying LINC00589's role in regulating drug resistance by interacting with miR-100, miR-452, and tumor suppressor genes. This research provides potential diagnostic markers and therapeutic targets for HER2-positive breast cancer.
Review
Oncology
Daniele Galanti, Alessandro Inno, Maria La Vecchia, Nicolo Borsellino, Lorena Incorvaia, Antonio Russo, Stefania Gori
Summary: Brain metastases are often associated with HER2+ breast cancer, and systemic therapy with trastuzumab has been the mainstay. Other HER2-targeted agents have been introduced in clinical practice, with newer agents such as neratinib, tucatinib, and trastuzumab deruxtecan showing interesting activity against brain metastases. Further research is needed to elucidate the optimal sequence of these agents and their combination with local treatment.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Article
Medicine, General & Internal
Xiaoping Ma, Yan Li, Li Li, Chunyan Gao, Dan Liu, Hongyu Li, Zhenhui Zhao, Bing Zhao
Summary: The study explored effective methods through combining pyrotinib to treat brain metastasis with HER2-positive advanced breast cancer. Pyrotinib-based combination therapy was found to be safe and efficient for treating HER2-positive brain metastasis, with pyrotinib combined with nab-paclitaxel showing superior efficacy.
ANNALS OF MEDICINE
(2022)
Article
Oncology
Guy Jerusalem, Yeon Hee Park, Toshinari Yamashita, Sara A. Hurvitz, Shanu Modi, Fabrice Andre, Ian E. Krop, Xavier Gonzalez Farre, Benoit You, Cristina Saura, Sung-Bae Kim, Cynthia R. Osborne, Rashmi K. Murthy, Lorenzo Gianni, Toshimi Takano, Yali Liu, Jillian Cathcart, Caleb Lee, Christophe Perrin
Summary: The DESTINY-Breast01 study evaluated the efficacy of trastuzumab deruxtecan in heavily pretreated HER2-positive metastatic breast cancer patients, and found that it showed durable clinical activity in patients with treated brain metastases.
Editorial Material
Oncology
Alicia F. C. Okines, Nicholas C. Turner
Summary: HER2 amplification heterogeneity is linked to resistance to trastuzumab emtansine in the neoadjuvant setting, highlighting the significance of determining whether varying HER2-positive cancer types require distinct treatment approaches.
Article
Oncology
Charles L. Vogel, Melody A. Cobleigh, Debu Tripathy, John C. Gutheil, Lyndsay N. Harris, Louis Fehrenbacher, Dennis J. Slamon, Maureen Murphy, William F. Novotny, Michael Burchmore, Steven Shak, Stanford J. Stewart, Michael Press
Summary: The purpose of this study was to evaluate the efficacy and safety of single-agent trastuzumab as first-line treatment in women with HER2-positive metastatic breast cancer. The results showed that single-agent trastuzumab had good efficacy and tolerability in the treatment of HER2-positive metastatic breast cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Clinical Neurology
Ramin A. Morshed, Jacob S. Young, Andrew J. Gogos, Alexander F. Haddad, James T. McMahon, Annette M. Molinaro, Vivek Sudhakar, Nadeem Al-Adli, Shawn L. Hervey-Jumper, Mitchel S. Berger
Summary: The study found that in glioma patients, repeat craniotomies are not significantly more prone to complications compared to initial surgeries, and the complication rates were lower than those reported in literature. Older age and significant leukocytosis due to steroid use were identified as predictors of complications.
ACTA NEUROCHIRURGICA
(2022)
Article
Cell Biology
Dhrutiy Patel, Aarsh M. Dabhi, Crismita Dmello, Mahendra Seervi, K. M. Sneha, Pavan Agrawal, Mayurbhai H. Sahani, Deepak Kanojia
Summary: HNSCC is the sixth most common malignancy globally, with etiology including factors like tobacco, alcohol, and human papillomavirus infection. Analysis of independent gene expression datasets revealed that overexpression of ATG12, HSP90AB1, and FKBP1A is associated with poor prognosis in HNSCC, while overexpression of ANXA1, FOS, and ULK3 is associated with improved prognosis.
CELL BIOLOGY INTERNATIONAL
(2022)
Article
Oncology
Sheantel J. Reihl, Nirav Patil, Ramin A. Morshed, Mulki Mehari, Alexander Aabedi, Ugonma N. Chukwueke, Alyx B. Porter, Valy Fontil, Gino Cioffi, Kristin Waite, Carol Kruchko, Quinn Ostrom, Jill Barnholtz-Sloan, Shawn L. Hervey-Jumper
Summary: The study revealed that minorities and women are still underrepresented in therapeutic clinical trials for neuroepithelial tumors relative to disease incidence and mortality. However, there has been improvement in study accrual over time.
Article
Clinical Neurology
Alexander A. Aabedi, Jacob S. Young, Yalan Zhang, Simon Ammanuel, Ramin A. Morshed, Cecilia Dalle Ore, Desmond Brown, Joanna J. Phillips, Nancy Ann Oberheim Bush, Jennie W. Taylor, Nicholas Butowski, Jennifer Clarke, Susan M. Chang, Manish Aghi, Annette M. Molinaro, Mitchel S. Berger, Shawn L. Hervey-Jumper
Summary: Resection of contrast-enhanced and non-contrast-enhanced tissue affects survival outcomes in glioblastoma patients. Postoperative neurological impairment is a key factor in predicting survival outcomes.
Article
Multidisciplinary Sciences
Alex Cordero, Matthew D. Ramsey, Deepak Kanojia, Jawad Fares, Edgar Petrosyan, Charles W. Schwartz, Rachel Burga, Peng Zhang, Aida Rashidi, Brandyn Castro, Ting Xiao, Catalina Lee-Chang, Jason Miska, Irina Balyasnikova, Atique U. Ahmed, Maciej S. Lesniak
Summary: This study engineered neural stem cells to secrete antibodies against HER2, inhibiting the progression of breast cancer brain metastases. The combination therapy with the tyrosine kinase inhibitor tucatinib showed promising results in animal models.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Article
Clinical Neurology
Daniel D. Cummins, Ramin A. Morshed, Miguel M. Chavez, Lauro N. Avalos, Vivek Sudhakar, Jason E. Chung, Aaron Gallagher, Satvir Saggi, Mariza Daras, Steve Braunstein, Philip Theodosopoulos, Michael W. McDermott, Manish K. Aghi
Summary: Salvage surgery may be effective in controlling brain metastases after previous stereotactic radiosurgery (SRS), especially when combined with adjuvant therapies such as brachytherapy and repeat SRS. Presence of extracranial malignancy is associated with shorter survival.
WORLD NEUROSURGERY
(2022)
Article
Clinical Neurology
Ramin A. Morshed, Jacob S. Young, Megan Casey, Elaina J. Wang, Manish K. Aghi, Mitchel S. Berger, Shawn L. Hervey-Jumper
Summary: Elderly patients with GBM can have acceptable outcomes after surgical resection, followed by adjuvant chemotherapy and radiation therapy. In addition to treatment factors, a decreased masseter diameter on preoperative imaging, indicating sarcopenia, is associated with shorter overall survival and 90-day mortality after surgical resection.
WORLD NEUROSURGERY
(2022)
Article
Oncology
Crismita Dmello, Aaron Sonabend, Victor A. Arrieta, Daniel Y. Zhang, Deepak Kanojia, Li Chen, Andrew Gould, Jiangshan Zhang, Seong Jae Kang, Jan Winter, Craig Horbinski, Christina Amidei, Balazs Gyorffy, Alex Cordero, Catalina Lee Chang, Brandyn Castro, Patrick Hsu, Atique U. Ahmed, Maciej S. Lesniak, Roger Stupp, Adam M. Sonabend
Summary: By analyzing genome-wide CRISPR knockout screen results and patient data, researchers identified endoplasmic reticulum protein SSR3 as a potential predictive biomarker for susceptibility to Paclitaxel in breast cancer and glioblastoma.
CLINICAL CANCER RESEARCH
(2022)
Article
Clinical Neurology
Joseph H. Garcia, Caleb Rutledge, Ethan A. Winkler, Luis Carrete, Ramin A. Morshed, Alex Y. Lu, Satvir Saggi, Christine K. Fox, Heather J. Fullerton, Helen Kim, Daniel L. Cooke, Steven W. Hetts, Michael T. Lawton, Nalin Gupta, Adib A. Abla
Summary: Pediatric brain arteriovenous malformations (AVMs) are a leading cause of spontaneous intracranial hemorrhage (SICH) in children. This study validates the recently created Ruptured Arteriovenous Malformation Grading Scale (RAGS) in a cohort of pediatric patients with AVMs, and demonstrates that the RAGS score outperforms other clinical grading scales in predicting clinical outcomes.
JOURNAL OF NEUROSURGERY-PEDIATRICS
(2022)
Article
Oncology
Jacob S. Young, Ramin A. Morshed, Shawn L. Hervey-Jumper, Mitchel S. Berger
Summary: Following updates to the WHO pathological criteria, all major neuro-oncology societies in North America and Europe now advocate for maximal safe resection as the initial management for diffuse gliomas. Surgical plans for both low- and high-grade gliomas should aim to achieve supramaximal resection based on preoperative imaging and the patient's performance status, with preservation of functional cortical and subcortical regions. This summary statement highlights the tools and technologies that facilitate safe removal of diffuse gliomas, along with management strategies to minimize complications and the potential for further biological discoveries and improved delivery of adjuvant therapies.
Article
Clinical Neurology
Ramin A. Morshed, Anthony T. Lee, Elaina J. Wang, Jacob S. Young, Soonmee Cha, Shawn L. Hervey-Jumper, Mitchel S. Berger
Summary: This study retrospectively analyzed the surgical outcomes and postoperative neurological deficits of 39 patients with diffuse gliomas within the middle frontal gyrus. The results showed that extensive resection of these gliomas had minimal risk for long-term morbidity. Partial subcortical tract interruption may lead to transient but not permanent deficits.
JOURNAL OF NEUROSURGERY
(2022)
Article
Clinical Neurology
Jacob S. Young, Andrew J. Gogos, Alexander A. Aabedi, Ramin A. Morshed, Matheus P. Pereira, Samuel Lashof-Regas, Ziba Mansoori, Tracy Luks, Shawn L. Hervey-Jumper, Javier E. Villanueva-Meyer, Mitchel S. Berger
Summary: This study aimed to identify which patients with SMA gliomas would develop a postoperative SMA syndrome. The results showed that more extensive resections involving the posterior SMA region and posterior cingulate gyrus increased the likelihood of postoperative SMA syndrome.
JOURNAL OF NEUROSURGERY
(2022)
Article
Clinical Neurology
Maria R. H. Castro, Stephen T. Magill, Ramin A. Morshed, Jacob S. Young, Steve E. Braunstein, Michael W. McDermott, Edward F. Chang
Summary: Most patients with facial sensory symptoms caused by meningiomas or vestibular schwannomas (VSs) experienced improvement after tumor resection. Surgery led to immediate and sustained improvement in pain and paresthesias, whereas numbness was slower to improve. Patients with smaller tumors and complete decompression of the trigeminal nerve were more likely to experience improvement in facial pain.
JOURNAL OF NEUROSURGERY
(2022)
Article
Biochemistry & Molecular Biology
Ratika Kunder, Michelle Velyunskiy, Sara F. Dunne, Byoung-Kyu Cho, Deepak Kanojia, Lauren Begg, Adrienne M. Orriols, Erica Fleming-Trujillo, Pranathi Vadlamani, Alesia Vialichka, Rosemary Bolin, Jessica N. Perrino, Diane Roth, Matthew R. Clutter, Nicolette A. Zielinski-Mozny, Young Ah Goo, Massimo Cristofanilli, Marc L. Mendillo, Athanassios Vassilopoulos, Dai Horiuchi
Summary: Triple-negative breast cancer (TNBC) is a subtype with poor clinical outcomes, characterized by overexpression of PIM kinases. Preclinical data suggests sensitivity of TNBC with elevated MYC expression to PIM inhibition. Combination therapy of PIM and 20S proteasome inhibitors show synergistic antitumor effects against MYC-overexpressing TNBC.
CELL CHEMICAL BIOLOGY
(2022)
Review
Clinical Neurology
Ramin A. Morshed, Nicole T. Jiam, Elaina J. Wang, Stephen T. Magill, Renata M. Knoll, Elliott D. Kozin, Philip Theodosopoulos, Steven W. Cheung, Jeffrey D. Sharon, Michael W. McDermott
Summary: This study found that posterior fossa meningiomas involving the endolymphatic sac can cause Meniere's syndrome. Early recognition and microsurgical excision of these tumors are crucial for relieving most symptoms and stabilizing hearing loss.
JOURNAL OF NEUROSURGERY
(2022)
